In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 106778-43-2, name is 6-Isoquinolinecarboxylic Acid, introducing its new discovery. name: 6-Isoquinolinecarboxylic Acid
Azole-based inhibitors of AKT/PKB for the treatment of cancer
Through a combination of screening and structure-based rational design, we have discovered a series of N1-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines that were developed into potent ATP competitive inhibitors of AKT. Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions observed in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA. One compound was shown to have acceptable pharmacokinetic properties and to be a potent inhibitor of AKT signaling and of in vivo xenograft tumor growth in a preclinical model of glioblastoma.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 106778-43-2, and how the biochemistry of the body works.name: 6-Isoquinolinecarboxylic Acid
Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H1654N – PubChem